Journal of Neural Transmission

, Volume 117, Issue 3, pp 333–342

Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility—an open-label, 6-week study

  • Karla Eggert
  • Örjan Skogar
  • Khaled Amar
  • Liisa Luotonen
  • Mikko Kuoppamäki
  • Mika Leinonen
  • Helena Nissinen
  • Wolfgang Oertel
Movement Disorders - Original Article

DOI: 10.1007/s00702-009-0344-4

Cite this article as:
Eggert, K., Skogar, Ö., Amar, K. et al. J Neural Transm (2010) 117: 333. doi:10.1007/s00702-009-0344-4

Abstract

The study objective was to assess the efficacy, safety and feasibility of switching from levodopa/benserazide (LB) or levodopa/carbidopa (LC) to levodopa/carbidopa/entacapone (LCE) in Parkinson’s disease (PD) patients with wearing-off. This was a multicenter, open-label, 6-week study; the primary outcome was success rate based on the patient-assessed Clinical Global Impression of Change (P-CGI-C). Secondary outcomes included investigator-assessed CGI-C (I-CGI-C), change from baseline in Unified Parkinson’s Disease Rating Scale (UPDRS), motor/non-motor wearing-off symptoms and quality of life–visual analog scale (QoL-VAS). After switching to LCE, 77% of patients reported an ‘improvement’ (p < 0.0001 vs. patients reporting ‘no change or worsening’). Significant improvements were seen in I-CGI-C, UPDRS and QoL-VAS, regardless of prior therapy. Oral levodopa dosing was increased in 28% of patients; the primary outcome remained significant when these patients were excluded. The data suggest that switching from LB/LC to LCE provided a significant benefit in PD patients with wearing-off.

Keywords

LevodopaEntacaponeCarbidopaBenserazideWearing-off9-item Wearing-off Questionnaire

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Karla Eggert
    • 1
  • Örjan Skogar
    • 2
  • Khaled Amar
    • 3
  • Liisa Luotonen
    • 4
  • Mikko Kuoppamäki
    • 4
    • 5
  • Mika Leinonen
    • 6
  • Helena Nissinen
    • 7
  • Wolfgang Oertel
    • 1
  1. 1.Department of NeurologyPhilipps-University MarburgMarburgGermany
  2. 2.Länssjukhuset RyhovJönköpingSweden
  3. 3.Royal Bournemouth HospitalBournemouthUK
  4. 4.Orion PharmaTurkuFinland
  5. 5.Department of NeurologyUniversity of TurkuTurkuFinland
  6. 6.4PharmaKistaSweden
  7. 7.Orion PharmaEspooFinland